President Biden today announced a major partnership between Johnson & Johnson and Merck to manufacture the latest COVID-19 vaccine to be authorized for emergency use in the U.S.

The arrangement includes activating the Defense Production Act to help equip two Merck facilities to produce the Johnson & Johnson vaccine, including a fill-finish facility to fill vials and package shots for distribution. The other facility will produce the vaccine itself.

The arrangement is expected to boost lagging Johnson & Johnson supply issues, which will fall significantly short of an initial goal of delivering 12 million shots by the end of February. Instead, Johnson & Johnson, whose vaccine earned a Food and Drug Administration emergency use authorization over the weekend, revised its expectations to 20 million does by the end of March, and 100 million by June.

Related News Articles

Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…